Maxim Positive on Onconova Therapeutics (ONTX) Following Q2 Report; Notes Accelerating INSPIRE Enrollment

August 15, 2016 2:53 PM

Maxim affirms Onconova Therapeutics (NASDAQ: ONTX) at Buy with a price target of $6 following Q2 results and update issued Monday.

Analyst Jason McCarthy noted the following key points today:

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Categories

Analyst Comments

Next Articles